Cost Effectiveness of Recombinant Human Insulin-Like Growth Factor I Therapy in Patients with ALS

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.15, Iss.2, 1999-02, pp. : 179-195

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The insulin-like growth factor-I receptor as a target for cancer therapy

By Baserga Renato

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 4, 2005-08 ,pp. : 753-768

Informa Healthcare

Access to resources Recommend Favorite

Insulin-Like Growth Factor I: Implications in Aging

By Arvat E. Broglio F. Ghigo E.

Drugs & Aging, Vol. 16, Iss. 1, 2000-01 ,pp. : 29-40

Adis International

Access to resources Recommend Favorite

Insulin-like growth factor-I and parathyroid

By Rosen C.J.

Expert Opinion on Investigational Drugs, Vol. 6, Iss. 9, 1997-09 ,pp. : 1193-1198

Informa Healthcare

Access to resources Recommend Favorite

Effect of Insulin-Like Growth Factor-I Gene Therapy on the Somatotropic Axis in Experimental Prolactinomas

Cells Tissues Organs, Vol. 190, Iss. 1, 2008-10 ,pp. : 20-26

Karger

Access to resources Recommend Favorite

Morphological Changes Induced by Insulin-Like Growth Factor-I Gene Therapy in Pituitary Cell Populations in Experimental Prolactinomas

Cells Tissues Organs, Vol. 191, Iss. 4, 2009-11 ,pp. : 316-325

Karger

Access to resources Recommend Favorite